Étiquette : sociologie

Alessandro Stella, Publications, 2019

Alessandro Stella Directeur de recherche CNRS Equipe(s) : GEI Laboratoire(s) de rattachement : CRH Coordonnées professionnelles EHESS-CRH GEI (Bureau A 04-11) 54, boulevard Raspail 75006 Paris alessandro.stella (a) wanadoo.fr 01 49 54 24 42 http://gei.ehess.fr/index.php?942  Diplômes 1987 : Diplôme de l’EHESS, sous la direction de Mme Christiane Klapisch-Zuber : « Sur les traces laissées par les Ciompi en révolte : les hommes, les lieux, le travail », rapporteur M. Jacques Le Goff. Prix du meilleur diplôme de l’EHESS. 1992 : Doctorat de l’EHESS, sous la direction de Mme Christiane Klapisch-Zuber : « Un tableau florentin du Trecento. Fiscalité, topographie et société dans la deuxième moitié du XIVe siècle ». Mention : « Très honorable ». 2007 : Habilitation à Diriger des Recherches, Université [...]

Lire la suite

Psychiatry might need some psychedelic therapy, Matthew W. Johnson, 2018

Psychiatry might need some psychedelic therapy Matthew W. Johnson International Review of Psychiatry, 2018, 30, 4, 285-290, DOI: 10.1080/09540261.2018.1509544   EDITORIAL Psychiatry might need some psychedelic therapy In historical and modern-day studies, psychedelic drugs have shown promise in managing a variety of psychiatric disorders, but their medical use has often raised controversies. The controversies have related to social, political, and legal challenges. History Although anthropological evidence suggests that classic psychedelic drugs (hereafter, ‘psychedelics’) have been used by various indigenous peoples as sacraments and healing agents before recorded history, in the mid-twentieth century they came to occupy a place at the cutting edge of psychiatric research (Johnson, Richards, & Griffiths, [...]

Lire la suite

Potential Therapeutic Effects of Psilocybin, Matthew W. Johnson & Roland R. Griffiths, 2017

Potential Therapeutic Effects of Psilocybin Matthew W. Johnson & Roland R. Griffiths Neurotherapeutics, 2017, 14, 734–740 DOI 10.1007/s13311-017-0542-y Abstract Psilocybin and other 5-hydroxytryptamine2A agonist classic psychedelics have been used for centuries as sacraments within indigenous cultures. In the mid-twentieth century they were a focus within psychiatry as both probes of brain function and experimental therapeutics. By the late 1960s and early 1970s these scientific inquires fell out of favor because classic psychedelics were being used outside of medical research and in association with the emerging counter culture. However, in the twenty-first century, scientific interest in classic psychedelics has returned and grown as a result of [...]

Lire la suite

Psychedelics and Mental Health : A Population Study, Teri S. Krebs & Pal-Ørjan Johansen, 2013

Psychedelics and Mental Health : A Population Study Teri S. Krebs, Pal-Ørjan Johansen PLoS ONE, 2013, 8, (8): e63972. doi:10.1371/journal.pone.0063972   Abstract Background : The classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. Clinical studies do not suggest that psychedelics cause long-term mental health problems. Psychedelics have been used in the Americas for thousands of years. Over 30 million people currently living in the US have used LSD, psilocybin, or mescaline. Objective : To evaluate the association between the lifetime use of psychedelics and current mental health in the adult population. Method : Data drawn from years 2001 [...]

Lire la suite

Predicting Responses to Psychedelics : A Prospective Study, Eline C. H. M. Haijen et al., 2018

Predicting Responses to Psychedelics : A Prospective Study Eline C. H. M. Haijen, Mendel Kaelen, Leor Roseman, Christopher Timmermann, Hannes Kettner, Suzanne Russ, David Nutt, Richard E. Daws, Adam D. G. Hampshire, Romy Lorenz  and Robin L. Carhart-Harris Frontiers in Pharmacology, 2018 doi: 10.3389/fphar.2018.00897   Abstract Responses to psychedelics are notoriously difficult to predict, yet significant work is currently underway to assess their therapeutic potential and the level of interest in psychedelics among the general public appears to be increasing. We aimed to collect prospective data in order to improve our ability to predict acute- and longer-term responses to psychedelics. Individuals who planned to take a [...]

Lire la suite

Perceptions of the medicinal value of hallucinogenic drugs among college students, Jared I. WILDBERGER et al., 2017

Perceptions of the medicinal value of hallucinogenic drugs among college students JARED I. WILDBERGER, CASSANDRA N. JOHN and ROBERT M. HALLOCK Journal of Psychedelic Studies, 2017, 1(2), pp. 50–54 DOI: 10.1556/2054.01.2017.008   Background : This survey examined perceptions among college students about the potential medicinal benefits of hallucinogenic drugs. Current research and potential benefits include an ability to help anxiety, post-traumatic stress disorder, and addiction with hallucinogen-assisted psychotherapy. Methods : We devised and administered a survey on 124 students at two college campuses, one small private college in the mid-Atlantic and one medium-sized public university in the Midwest of the United States. Results: Responses were similar [...]

Lire la suite

Inclusion of people of color in psychedelic-assisted psychotherapy : a review of the literature, Timothy I. Michaels et al., 2018

Inclusion of people of color in psychedelic-assisted psychotherapy : a review of the literature Timothy I. Michaels, Jennifer Purdon, Alexis Collins and Monnica T. Williams BMC Psychiatry, 2018, 18, 245 https://doi.org/10.1186/s12888-018-1824-6 Abstract Background : Despite renewed interest in studying the safety and efficacy of psychedelic-assisted psychotherapy for the treatment of psychological disorders, the enrollment of racially diverse participants and the unique presentation of psychopathology in this population has not been a focus of this potentially ground-breaking area of research. In 1993, the United States National Institutes of Health issued a mandate that funded research must include participants of color and proposals must include methods for [...]

Lire la suite

The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion, Jamilha R. George et al., 2019

The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion JAMILAH R. GEORGE, TIMOTHY I. MICHAELS, JAE SEVELIUS and MONNICA T. WILLIAMS Journal of Psychedelic Studies, 2019 DOI: 10.1556/2054.2019.015   In recent years, the study of psychedelic science has resurfaced as scientists and therapists are again exploring its potential to treat an array of psychiatric conditions, such as depression, post-traumatic stress disorder, and addiction. The scientific progress and clinical promise of this movement owes much of its success to the history of indigenous healing practices; yet the work of indigenous people, ethnic and racial minorities, women, [...]

Lire la suite

Menace or medicine? Anthropological perspectives on the self-administration of high potency cannabis in the UK, Anna Waldstein, 2010

Menace or medicine? Anthropological perspectives on the self-administration of high potency cannabis in the UK Anna Waldstein Drugs and Alcohol Today • Volume 10 Issue 3 • September 2010   Abstract Domestically produced, high potency cannabis (often referred to as ‘skunk’ in the mainstream UK media) has become increasingly widespread in the UK. This paper considers whether the trend reflects an increased awareness of and desire for medical marijuana. Determining whether cannabis is a drug or a medicine depends on its objective physiological effects – which may vary from one individual to another – as well as how and why those effects are experienced. The [...]

Lire la suite